| Record Information |
| Version |
3.5 |
| Creation Date |
2006-08-12 17:33:54 -0600 |
| Update Date |
2013-02-08 17:12:38 -0700 |
| HMDB ID |
HMDB03550 |
| Secondary Accession Numbers |
|
| Metabolite Identification |
| Common Name |
Calcidiol |
| Description |
The major circulating metabolite of vitamin D3 (calciferon). It is produced in the liver and is the best indicator of the body's vitamin D stores. It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties. |
| Structure |
Download:
MOL |
SDF |
SMILES |
InChI
Display:
2D Structure |
3D Structure
|
| Synonyms |
- 25-Hydroxy-cholecalciferol
- 25-Hydroxycholecalciferol
- 25-Hydroxyvitamin D3
- 5,6-cis-25-Hydroxyvitamin D3
- 9,10-Secocholesta-5,7,10(19)-triene-3b,25-diol
- Calcidiol
- Calcifediol
- Calcifediol anhydrous
- Calderol
- Didrogyl
- Hidroferol
|
| Chemical Formula |
C27H44O2 |
| Average Molecular Weight |
400.6371 |
| Monoisotopic Molecular Weight |
400.334130652 |
| IUPAC Name |
(1S,3Z)-3-{2-[(1R,3aS,4E,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexan-1-ol |
| Traditional IUPAC Name |
25-hydroxycholecalciferol |
| CAS Registry Number |
19356-17-3 |
| SMILES |
C[C@H](CCCC(O)(C)C)[C@@]1([H])CC[C@@]2([H])\C(CCC[C@]12C)=C\C=C1\C[C@@H](O)CCC1=C |
| InChI Identifier |
InChI=1S/C27H44O2/c1-19-10-13-23(28)18-22(19)12-11-21-9-7-17-27(5)24(14-15-25(21)27)20(2)8-6-16-26(3,4)29/h11-12,20,23-25,28-29H,1,6-10,13-18H2,2-5H3/b21-11+,22-12-/t20-,23+,24-,25+,27-/m1/s1 |
| InChI Key |
JWUBBDSIWDLEOM-DTOXIADCSA-N |
| Chemical Taxonomy |
| Kingdom |
Organic Compounds |
| Super Class |
Lipids |
| Class |
Prenol Lipids |
| Sub Class |
Sesterterpenes |
| Other Descriptors |
- Aliphatic Homopolycyclic Compounds
- Vitamin D and Derivatives
|
| Substituents |
- Cyclic Alcohol
- Cyclohexane
- Secondary Alcohol
- Steroid
- Tertiary Alcohol
|
| Direct Parent |
Sesterterpenes |
| Ontology |
| Status |
Detected and Quantified |
| Origin |
|
| Biofunction |
- Cell signaling
- Fuel and energy storage
- Fuel or energy source
- Membrane integrity/stability
|
| Application |
- Nutrients
- Stabilizers
- Surfactants and Emulsifiers
|
| Cellular locations |
- Cytoplasm
- Extracellular
- Membrane (predicted from logP)
- Mitochondria
|
| Physical Properties |
| State |
Solid |
| Experimental Properties |
| Property |
Value |
Reference |
| Melting Point |
Not Available |
Not Available |
| Boiling Point |
Not Available |
Not Available |
| Water Solubility |
Not Available |
Not Available |
| LogP |
Not Available |
Not Available |
|
| Predicted Properties |
|
| Spectra |
|
|
| Biological Properties |
| Cellular Locations |
- Cytoplasm
- Extracellular
- Membrane (predicted from logP)
- Mitochondria
|
| Biofluid Locations |
|
| Tissue Location |
- Kidney
- Epidermis
- Prostate
- Gonads
|
| Pathways |
Not Available
|
| Normal Concentrations |
|
| Blood |
Detected and Quantified |
|
0.0689 (0.0459-0.0919) uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Blood |
Detected and Quantified |
|
0.13 (0.13-0.14) uM |
Adult (>18 years old) |
Both |
Normal |
After 1 week of high exposure to sun
|
| Blood |
Detected and Quantified |
|
0.0245 +/- 0.023 uM |
Adult (>18 years old) |
Both |
Normal |
Not Available |
| Urine |
Detected and Quantified |
|
0.092 +/- 0.0037 umol/mmol creatinine |
Adult (>18 years old) |
Both |
Normal |
Not Available |
|
| Abnormal Concentrations |
|
| Blood |
Detected and Quantified |
|
0.044 (0.013-0.074) uM |
Adult (>18 years old) |
Both |
Anephrism |
Not Available |
| Urine |
Detected and Quantified |
|
0.0099 +/- 0.0019 umol/mmol creatinine |
Adult (>18 years old) |
Both |
Nephrotic syndrome |
Not Available |
|
| Associated Disorders and Diseases |
| Disease References |
| Anephric patients |
- Shepard RM, Horst RL, Hamstra AJ, DeLuca HF: Determination of vitamin D and its metabolites in plasma from normal and anephric man. Biochem J. 1979 Jul 15;182(1):55-69.
Pubmed: 227368
|
| Nephrotic syndrome |
- Goldstein DA, Haldimann B, Sherman D, Norman AW, Massry SG: Vitamin D metabolites and calcium metabolism in patients with nephrotic syndrome and normal renal function. J Clin Endocrinol Metab. 1981 Jan;52(1):116-21.
Pubmed: 6969729
|
|
| Associated OMIM IDs |
None |
| External Links |
| DrugBank ID |
DB00146  |
| Phenol Explorer Compound ID |
Not Available |
| Phenol Explorer Metabolite ID |
Not Available |
| FoodDB ID |
FDB021782 |
| KNApSAcK ID |
Not Available |
| Chemspider ID |
4446820  |
| KEGG Compound ID |
C01561  |
| BioCyc ID |
CALCIDIOL  |
| BiGG ID |
2289142  |
| Wikipedia Link |
Calcidiol  |
| NuGOwiki Link |
HMDB03550  |
| Metagene Link |
HMDB03550  |
| METLIN ID |
6949  |
| PubChem Compound |
5283731  |
| PDB ID |
VDY  |
| ChEBI ID |
17933  |
| References |
| Synthesis Reference |
Mascarenas, J. L.; Mourino, A.; Castedo, L. Studies on the synthesis of side-chain hydroxylated metabolites of vitamin D. 3. Synthesis of 25-ketovitamin D3 and 25-hydroxyvitamin D3. Journal of Organic Chemistry (1986), 51(8), 1269-72. |
| Material Safety Data Sheet (MSDS) |
Download (PDF)
|
| General References |
- Shepard RM, Horst RL, Hamstra AJ, DeLuca HF: Determination of vitamin D and its metabolites in plasma from normal and anephric man. Biochem J. 1979 Jul 15;182(1):55-69.
Pubmed: 227368
- Passadakis P, Ersoy F, Tam P, Memmos D, Siamopoulos K, Ozener C, Akcicek F, Camsari T, Ates K, Ataman R, Vlachojannis J, Dombros N, Utas C, Akpolat T, Bozfakioglu S, Wu GG, Karayaylali I, Arinsoy T, Stathakis C, Yavuz M, Tsakiris D, Dimitriades A, Yilmaz ME, Gultekin M, Karayalcin B, Challa A, Polat N, Oreopoulos DG: Serum levels of prostate-specific antigen and vitamin D in peritoneal dialysis patients. Adv Perit Dial. 2004;20:203-8.
Pubmed: 15384827
- Park SB, Suh DH, Youn JI: A pilot study to assess the safety and efficacy of topical calcipotriol treatment in childhood psoriasis. Pediatr Dermatol. 1999 Jul-Aug;16(4):321-5.
Pubmed: 10469423
- Haden ST, Fuleihan GE, Angell JE, Cotran NM, LeBoff MS: Calcidiol and PTH levels in women attending an osteoporosis program. Calcif Tissue Int. 1999 Apr;64(4):275-9.
Pubmed: 10089217
- Flanagan JN, Young MV, Persons KS, Wang L, Mathieu JS, Whitlatch LW, Holick MF, Chen TC: Vitamin D metabolism in human prostate cells: implications for prostate cancer chemoprevention by vitamin D. Anticancer Res. 2006 Jul-Aug;26(4A):2567-72.
Pubmed: 16886665
- Gacad MA, Adams JS: Proteins in the heat shock-70 family specifically bind 25-hydroxyvitamin D3 and 17beta-estradiol. J Clin Endocrinol Metab. 1998 Apr;83(4):1264-7.
Pubmed: 9543154
- Feingold KR, Williams ML, Pillai S, Menon GK, Halloran BP, Bikle DD, Elias PM: The effect of vitamin D status on cutaneous sterologenesis in vivo and in vitro. Biochim Biophys Acta. 1987 Sep 14;930(2):193-200.
Pubmed: 3040120
- DeLuca HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr. 2004 Dec;80(6 Suppl):1689S-96S.
Pubmed: 15585789
|